Physician profile
Akbar Obaray
NPI 1104863299
$13,577.93
in general payments reported to CMS, 2019-2025
21 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $7,287 · 2021: $2,887 · 2022: $560 · 2023: $990 · 2024: $435 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,488.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $10,219.03 | 2020-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,974.34 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Philips North America LLC | $516.08 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy, Patient Interface Software |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.56 | 2022-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $135.00 | 2025 | Zepbound |
| Amarin Pharma, INC. | $129.80 | 2019 | |
| Genzyme Corporation | $56.31 | 2023 | |
| Mylan Specialty L.P. | $49.61 | 2022-2023 | Yupelri |
| Jazz Pharmaceuticals INC. | $45.45 | 2022-2025 | |
| United Therapeutics Corporation | $43.82 | 2023-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $42.54 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $38.55 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.96 | 2023 | Aralast |
| Resmed Corp | $31.81 | 2023 | |
| Genentech USA, INC. | $25.43 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $17.87 | 2023 | Dupixent |
| Ani Pharmaceuticals, INC. | $17.85 | 2023 | Purified Cortrophin Gel |
| Baxter Healthcare | $14.86 | 2023 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $14.38 | 2023 | Tezspire |
| Insmed, INC. | $13.39 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akbar Obaray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.